-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Lowered to $31 at Goldman Sachs
-
-
-
-
-
-
-
Viridian Therapeutic (VRDN) PT Lowered to $29 at Jefferies
-
-
-
-
-
-
-
Stifel on Viridian Therapeutic (VRDN): 'We think shares can trade in the $40+ range'
-
-
-
-
-
-
-
Jefferies on Viridian Therapeutic (VRDN): 'Attractive 2026 Setup With Pot'l Launch and Pivotal Data', 'one of our Top Picks in 2026'
-
-
-
-
-
-
-
William Blair Starts Viridian Therapeutic (VRDN) at Outperform
-
-
-
-
-
-
-
Viridian completes enrollment in phase 3 thyroid eye disease trials
-
-
-
-
-
-
-
Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'
-
416,567 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

